Texas is currently home to 4873 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Recruiting
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Texas Oncology - Amarillo, Amarillo, Texas
Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/18/2025
Locations: The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Multi-center Evaluation of the Clinical Utility of ESD in the Western Population
Recruiting
The aim of this multi-center study is to prospectively document the clinical utility of ESD.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/18/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Endoscopic Submucosal Dissection
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Cardiothoracic and Vascular Surgeons, Austin, Texas
Conditions: Non-Small Cell Lung Cancer
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Recruiting
The Increlex® Global Registry is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The main purpose of this global registry is to collect, analyse and report safety data during and up to at least 5 years after the end of treatment in children and adolescents receiving Increlex® therapy for SPIGFD according to the locally approved product information.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
06/18/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: IGF1 Deficiency
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Recruiting
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Dren Investigational Site, Austin, Texas
Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Recruiting
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2025
Locations: Exelixis Clinical Site #2, San Antonio, Texas
Conditions: Hepatic Impairment, Moderate Hepatic Impairment
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Recruiting
The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD... Read More
Gender:
ALL
Ages:
Between 3 years and 20 years
Trial Updated:
06/17/2025
Locations: Texas Children's Hopsital (NT-DMT), Houston, Texas
Conditions: Sickle Cell Disease (SCD)
SPYRAL GEMINI Pilot Study
Recruiting
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with and without high cardiovascular risk.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/17/2025
Locations: Baylor Heart & Vascular Hospital, Dallas, Texas
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
06/17/2025
Locations: Local Institution - 0036, Austin, Texas
Conditions: Juvenile Psoriatic Arthritis
A Study of Oral E1018 in Healthy Adult Participants
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/17/2025
Locations: PPD Development, LP, Austin, Texas
Conditions: Malaria, Healthy Participants
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Recruiting
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Malignancies, Hematologic Malignancies